U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H31F3O5S
Molecular Weight 500.571
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUTICASONE PROPIONATE

SMILES

[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])C[C@H](F)C4=CC(=O)C=C[C@]34C

InChI

InChIKey=WMWTYOKRWGGJOA-CENSZEJFSA-N
InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1

HIDE SMILES / InChI

Molecular Formula C25H31F3O5S
Molecular Weight 500.571
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/fluticasone.html

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis. Fluticasone propionate binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2 (through activation of lipocortin-1 (annexin)) which controls the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.0 nM [EC50]
0.7 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CUTIVATE

Approved Use

CUTIVATE® Ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adult patients.

Launch Date

6.6104643E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
23364 pg/mL
1000 μg single, intravenous
dose: 1000 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUTICASONE PROPIONATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14148 pg × h/mL
1000 μg single, intravenous
dose: 1000 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUTICASONE PROPIONATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.1 h
1000 μg single, intravenous
dose: 1000 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUTICASONE PROPIONATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9%
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUTICASONE PROPIONATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg single, oral
Highest studied dose
Dose: 16 mg
Route: oral
Route: single
Dose: 16 mg
Sources:
healthy, adult
2 mg 2 times / day multiple, intranasal
Highest studied dose
Dose: 2 mg, 2 times / day
Route: intranasal
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
healthy, adult
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
healthy, adult
1320 ug 1 times / day multiple, respiratory
Highest studied dose
Dose: 1320 ug, 1 times / day
Route: respiratory
Route: multiple
Dose: 1320 ug, 1 times / day
Sources:
healthy, adult
3520 ug single, respiratory
Highest studied dose
Dose: 3520 ug
Route: respiratory
Route: single
Dose: 3520 ug
Sources:
healthy, adult
25 ug 2 times / day steady, respiratory
Dose: 25 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 25 ug, 2 times / day
Sources:
unhealthy, children
n = 211
Health Status: unhealthy
Condition: Asthma
Age Group: children
Population Size: 211
Sources:
Other AEs: Pneumonia mycoplasmal...
Other AEs:
Pneumonia mycoplasmal (serious, 1 patient)
Sources:
50 ug 2 times / day steady, respiratory
Dose: 50 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 50 ug, 2 times / day
Sources:
unhealthy, children
n = 208
Health Status: unhealthy
Condition: Asthma
Age Group: children
Population Size: 208
Sources:
Other AEs: Disruptive mood dysregulation disorder...
Other AEs:
Disruptive mood dysregulation disorder (serious, 1 patient)
Sources:
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 314
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 314
Sources:
Other AEs: Thirst, Gastrointestinal viral infection...
Other AEs:
Thirst (below serious, 1 patient)
Gastrointestinal viral infection (below serious, 1 patient)
Headache (below serious, 2 patients)
Throat irritation (below serious, 1 patient)
Palpitations (below serious, 1 patient)
Laceration (below serious, 1 patient)
Hypertension (below serious, 1 patient)
Sources:
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Eosinophilic Esophagitis
Population Size: 19
Sources:
Other AEs: Esophageal candidiasis...
Other AEs:
Esophageal candidiasis (below serious, 5 patients)
Sources:
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Eosinophilic Esophagitis
Population Size: 28
Sources:
Other AEs: General system disorders NEC, General system disorders NEC...
Other AEs:
General system disorders NEC (below serious, 7 patients)
General system disorders NEC (below serious, 2 patients)
General system disorders NEC (below serious, 1 patient)
General system disorders NEC (below serious, 5 patients)
General system disorders NEC (below serious, 4 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Pneumonia mycoplasmal serious, 1 patient
25 ug 2 times / day steady, respiratory
Dose: 25 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 25 ug, 2 times / day
Sources:
unhealthy, children
n = 211
Health Status: unhealthy
Condition: Asthma
Age Group: children
Population Size: 211
Sources:
Disruptive mood dysregulation disorder serious, 1 patient
50 ug 2 times / day steady, respiratory
Dose: 50 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 50 ug, 2 times / day
Sources:
unhealthy, children
n = 208
Health Status: unhealthy
Condition: Asthma
Age Group: children
Population Size: 208
Sources:
Gastrointestinal viral infection below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 314
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 314
Sources:
Hypertension below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 314
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 314
Sources:
Laceration below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 314
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 314
Sources:
Palpitations below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 314
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 314
Sources:
Thirst below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 314
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 314
Sources:
Throat irritation below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 314
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 314
Sources:
Headache below serious, 2 patients
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
unhealthy
n = 314
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Population Size: 314
Sources:
Esophageal candidiasis below serious, 5 patients
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Eosinophilic Esophagitis
Population Size: 19
Sources:
General system disorders NEC below serious, 1 patient
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Eosinophilic Esophagitis
Population Size: 28
Sources:
General system disorders NEC below serious, 2 patients
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Eosinophilic Esophagitis
Population Size: 28
Sources:
General system disorders NEC below serious, 4 patients
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Eosinophilic Esophagitis
Population Size: 28
Sources:
General system disorders NEC below serious, 5 patients
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Eosinophilic Esophagitis
Population Size: 28
Sources:
General system disorders NEC below serious, 7 patients
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
unhealthy
n = 28
Health Status: unhealthy
Condition: Eosinophilic Esophagitis
Population Size: 28
Sources:
Overview

Overview

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
weak
yes [Km 3.8 uM]
yes [Km 5.2 uM]
yes [Km 5.3 uM]
yes (co-administration study)
Comment: Ritonavir A drug interaction trial with fluticasone propionate aqueous nasal spray in healthy subjects has shown that ritonavir (a strong CYP3A4 inhibitor) can significantly increase plasma fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations
Page: 14.0
PubMed

PubMed

TitleDatePubMed
Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids.
1999 Apr
Regulation of the action of hydrocortisone in airway epithelial cells by 11beta-hydroxysteroid dehydrogenase.
1999 Sep
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
2000 Aug
Transcriptional potencies of inhaled glucocorticoids.
2000 Jul
Inhibition of GM-CSF secretion by topical corticosteroids and nedocromil sodium. A comparison study using nasal polyp epithelial cells.
2000 May
Inhaled fluticasone propionate for chronic asthma.
2001
Systemic availability of inhaled budesonide and fluticasone propionate: healthy versus asthmatic lungs.
2001
Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.
2001
[Changes in biochemical inflammation markers in evaluation of the effectiveness of basic chemotherapy in bronchial asthma].
2001
[Effect of fluticasone propionate at half dose of beclomethasone dipropionate divided twice daily and once daily in asthmatics inhaling beclomethasone dipropionate 800 micrograms daily or more].
2001 Apr
[Topical corticosteroids, a timely class of drugs. A new class II topical corticosteroid: fluticasone propionate].
2001 Apr 7
Improvement in health care utilization and pulmonary function with fluticasone propionate in patients with steroid-dependent asthma at a National Asthma Referral Center.
2001 Aug
Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study.
2001 Aug
A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma.
2001 Aug 15
Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis.
2001 Aug 4
Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo.
2001 Feb
Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.
2001 Feb
One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma.
2001 Jan
Fluticasone propionate and budesonide do not influence bone metabolism in the long term treatment of asthma.
2001 Jan-Feb
Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions.
2001 Jan-Feb
Fluticasone propionate: a rare contact sensitizer.
2001 Jan-Feb
Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.
2001 Jul
A novel pharmacologic action of glucocorticosteroids on leukotriene C4 catabolism.
2001 Jul
GRbeta expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone.
2001 Jul
Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma.
2001 Jul 1
[Effect of FP inhalation and airway inflammation assessed by ECP in asthma].
2001 Jun
[Peak inspiratory flow rates attained by asthmatic patients through a dry-powder inhaler of fluticasone propionate].
2001 Jun
Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray.
2001 Jun
Safety of inhaled corticosteroid therapy in young children with asthma.
2001 Jun
Comparison of once daily fluticasone propionate aqueous nasal spray with once daily budesonide reservoir powder device in patients with perennial rhinitis.
2001 Jun
Presence of fluticasone propionate on human nasal mucosal surface and in human nasal tissue over a period of 24 h after intranasal application.
2001 Jun
Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system.
2001 Jun 19
Treatment of rhinitis medicamentosa with fluticasone propionate--an experimental study.
2001 Mar
Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast.
2001 Mar
Fluticasone inhibits but does not reverse allergen-induced structural airway changes.
2001 Mar
The comparison of the efficacy of fluticasone propionate with cetirizine in perennial allergic rhinitis.
2001 Mar-Apr
A comparison of the efficacy and safety of a half dose of fluticasone propionate with beclamethasone dipropionate and budesonide in childhood asthma.
2001 May
A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate.
2001 May
Comparison of the tissue affinity of glucocorticoids to human lung, nasal and skin tissue in vitro.
2001 Oct
The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast.
2001 Oct
[Japanese guideline for the diagnosis and management of bronchial asthma (1998)--its results and reversion].
2001 Oct
A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy.
2001 Sep
The penetration of 0.005% fluticasone propionate ointment in eyelid skin.
2001 Sep
Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone.
2001 Sep 1
Patents

Sample Use Guides

Usual Adult Dose for Dermatitis Cream/Ointment: Apply a thin film to affected area twice a day
Route of Administration: Topical
Pretreatment with Fluticasone propionate (10(-11) M to about 10(-7) M, 24 h) inhibited TNF-alpha-induced VCAM-1 mRNA expression in BEAS-2B in a dose-dependent manner
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:45:18 UTC 2023
Edited
by admin
on Wed Jul 05 22:45:18 UTC 2023
Record UNII
O2GMZ0LF5W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLUTICASONE PROPIONATE
EP   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
FLUTICASONE PROPIONATE [ORANGE BOOK]
Common Name English
ADVAIR COMPONENT FLUTICASONE PROPIONATE
Brand Name English
FLUTICASONE PROPIONATE [USP MONOGRAPH]
Common Name English
CUTIVATE
Brand Name English
S-FLUOROMETHYL 6.ALPHA., 9.ALPHA.-DIFLUORO-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-17.ALPHA.-PROPIONYLOXYANDROSTA-1,4-DIENE-17.BETA-. CARBOTHIOATE
Common Name English
FLIXOTIDE
Brand Name English
FLUTICASONE PROPIONATE [EP MONOGRAPH]
Common Name English
FLUTICASONE PROPIONATE COMPONENT OF DYMISTA
Common Name English
ARMONAIR RESPICLICK
Brand Name English
LIPO-102 COMPONENT FLUTICASONE PROPIONATE
Common Name English
FLUTICASONE PROPIONATE [JAN]
Common Name English
FLOVENT
Code English
CCI18781
Code English
FLUTICASONE PROPIONATE [USP-RS]
Common Name English
PF-00241939
Code English
FLUTICASONE PROPIONATE [MART.]
Common Name English
AIRDUO RESPICLICK COMPONENT FLUTICASONE PROPIONATE
Brand Name English
NSC-759889
Code English
DYMISTA COMPONENT FLUTICASONE PROPIONATE
Common Name English
FLUTICASONE PROPIONATE [USAN]
Common Name English
CCI-18781
Code English
XHANCE
Brand Name English
ADVAIR HFA COMPONENT FLUTICASONE PROPIONATE
Common Name English
Fluticasone propionate [WHO-DD]
Common Name English
ANDROSTA-1,4-DIENE-17-CARBOTHIOIC ACID, 6,9-DIFLUORO-11-HYDROXY-16-METHYL-3-OXO-17-(1-OXOPROPOXY)-, (6.ALPHA.,11.BETA.,16.ALPHA.,17.ALPHA.)-S-(FLUOROMETHYL) ESTER
Common Name English
FLUTICASONE PROPIONATE COMPONENT OF ADVAIR
Brand Name English
FLUTICASONE PROPIONATE COMPONENT OF AIRDUO RESPICLICK
Brand Name English
FLUTICASONE PROPIONATE [MI]
Common Name English
FLUTICASONE PROPIONATE COMPONENT OF ADVAIR HFA
Common Name English
FLUTICASONE-17-PROPIONATE
Common Name English
FLUTICASONE PROPIONATE [VANDF]
Common Name English
FLONASE
Brand Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 273208
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
EU-Orphan Drug EU/3/16/1815
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
FDA ORPHAN DRUG 319410
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
FDA ORPHAN DRUG 499815
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
NCI_THESAURUS C521
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
Code System Code Type Description
PUBCHEM
444036
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
EVMPD
SUB02241MIG
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
MERCK INDEX
M5510
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY Merck Index
WIKIPEDIA
FLUTICASONE PROPIONATE
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
ChEMBL
CHEMBL1473
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
DAILYMED
O2GMZ0LF5W
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
SMS_ID
100000092718
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
DRUG CENTRAL
1225
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
NSC
759889
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
FDA UNII
O2GMZ0LF5W
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
DRUG BANK
DB00588
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
USAN
W-145
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
CAS
80474-14-2
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
RS_ITEM_NUM
1285873
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
RXCUI
50121
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY RxNorm
IUPHAR
7080
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
NCI_THESAURUS
C29061
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
EPA CompTox
DTXSID8045511
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
CHEBI
31441
Created by admin on Wed Jul 05 22:45:18 UTC 2023 , Edited by admin on Wed Jul 05 22:45:18 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
PARENT -> DERIVATIVE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE INACTIVE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
PROTEIN BINDING (PLASMA PROTEIN) PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC TOPICAL
PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY FLOVENT HFA INHALATION AEROSOL

RESPICLICK INHLATION POWDER

XHANCE (TM)

FLOVENT DISKUS INHALATION POWDER

ORAL BIOAVAILABILITY PHARMACOKINETIC INHALATION, AEROSOL: ALMOST COMPLETE

INTRANASAL
PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC RENAL
PHARMACOKINETIC